Results

1–10 of 119 results for Aflibercept

A Phase I Study to Evaluate the Tie2 Agonist RO7446603, Alone or in Combination With Aflibercept orFaricimab, in Diabetic Macular Edema
Jeremiah Brown, MD, MS, FASRS
Annual Meeting Talks
2025
Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Eric W Schneider, MD
Annual Meeting Talks
2025
Early Insights From Real-World Use of Aflibercept 8 mg Among Eyes With Diabetic Macular Edema SwitchingFrom Other Anti-VEGF Agents
Michael Javaheri, MD
Annual Meeting Talks
2025
VERONA: End-of-Study Results From a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Afliberceptfor Diabetic Macular Edema
Yasha S Modi, MD
Annual Meeting Talks
2025
Volumetric Analysis of Hard Exudates on Optical Coherence Tomography: Biomarker Results of Faricimab vs Aflibercept From Phase 3 YOSEMITE/RHINE
Murtaza K Adam, MD
Annual Meeting Talks
2025
Pooled Safety Analysis of Aflibercept 8 mg in the CANDELA PHOTON and PULSAR Trials
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2023
Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection, 8 mg vs 2 mg: Post Hoc Analysis of the Phase 2 CANDELA Study
Priya Sharma Vakharia, MD
Annual Meeting Talks
2023
Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2023
Faricimab Reduces Macular Leakage vs Aflibercept in Patients With DME
Eric Nudleman, MD, PhD
Annual Meeting Talks
2023
Six Monthly Intravitreal Aflibercept to Improve Macular Perfusion in Diabetic Retinopathy Without Macular Edema
Yoon Jeon Kim, MD
Annual Meeting Talks
2023